These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23732299)

  • 21. Sorafenib regulating ERK signals pathway in gastric cancer cell.
    Juan LW; En LM; Hao L; Kai HY; Ju H
    Environ Toxicol Pharmacol; 2014 Sep; 38(2):438-43. PubMed ID: 25136776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERK-modulated intrinsic signaling and G(2)/M phase arrest contribute to the induction of apoptotic death by allyl isothiocyanate in MDA-MB-468 human breast adenocarcinoma cells.
    Tsai SC; Huang WW; Huang WC; Lu CC; Chiang JH; Peng SF; Chung JG; Lin YH; Hsu YM; Amagaya S; Yang JS
    Int J Oncol; 2012 Dec; 41(6):2065-72. PubMed ID: 23008020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
    Fernand VE; Losso JN; Truax RE; Villar EE; Bwambok DK; Fakayode SO; Lowry M; Warner IM
    Chem Biol Interact; 2011 Jul; 192(3):220-32. PubMed ID: 21457705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
    Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
    Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway.
    Karam M; Legay C; Auclair C; Ricort JM
    Exp Cell Res; 2012 Mar; 318(5):558-69. PubMed ID: 22245102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Org OD14 (LIVIAL) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MCF-7 and T-47D, and the hormone-independent MDA-MB-231, breast cancer cell lines.
    Chetrite GS; Kloosterboer HJ; Philippe JC; Pasqualini JR
    Anticancer Res; 1999; 19(1A):269-75. PubMed ID: 10226553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
    Yang YY; Huang YT; Lee TY; Chan CC; Yeh YC; Lee KC; Lin HC
    Liver Transpl; 2012 Nov; 18(11):1371-83. PubMed ID: 22847887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of cell survival, cell cycle progression, tumor growth and cyclooxygenase-2 activity in MDA-MB-231 breast cancer cells by camphorataimide B.
    Lin WL; Lee YJ; Wang SM; Huang PY; Tseng TH
    Eur J Pharmacol; 2012 Apr; 680(1-3):8-15. PubMed ID: 22329896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
    Murray M; Gillani TB; Ghassabian S; Edwards RJ; Rawling T
    Eur J Pharm Sci; 2018 Mar; 114():55-63. PubMed ID: 29223619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
    Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.
    Yao J; He Z; Chen J; Sun W; Fang H; Xu W
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6549-53. PubMed ID: 23021967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
    Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
    Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of PPARalpha in the growth inhibitory effect of arachidonic acid on breast cancer cells.
    Bocca C; Bozzo F; Martinasso G; Canuto RA; Miglietta A
    Br J Nutr; 2008 Oct; 100(4):739-50. PubMed ID: 18304389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening.
    Nguyen TV; Sleiman M; Moriarty T; Herrick WG; Peyton SR
    Biomaterials; 2014 Jul; 35(22):5749-59. PubMed ID: 24726537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
    Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
    Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells.
    Kacan T; Altun A; Altun GG; Kacan SB; Sarac B; Seker MM; Bahceci A; Babacan N
    Asian Pac J Cancer Prev; 2014; 15(7):3185-9. PubMed ID: 24815468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells.
    Tao C; Lin H; Chen S
    Gene; 2014 Nov; 552(1):106-15. PubMed ID: 25219752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells.
    Androutsopoulos VP; Ruparelia K; Arroo RR; Tsatsakis AM; Spandidos DA
    Toxicology; 2009 Oct; 264(3):162-70. PubMed ID: 19666078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib for the treatment of multiple myeloma.
    Gentile M; Martino M; Recchia AG; Vigna E; Morabito L; Morabito F
    Expert Opin Investig Drugs; 2016 Jun; 25(6):743-9. PubMed ID: 26998658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.